Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here is the list of some big stocks recording gains in the previous session.
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split.
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday.
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial
4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for…
SVB Leerink Maintains Market Perform on 4D Molecular Therapeutics, Raises Price Target to $15
SVB Leerink analyst Mani Foroohar maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Market Perform and raises the price target from $11 to $15.
4D Molecular Therapeutics Announces Interim Clinical Data From Ongoing Phase 1/2 Clinical Trial Of Intravitreal 4D-150 For Wet Age-Related Macular Degeneration
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
SVB Leerink Maintains Market Perform on 4D Molecular Therapeutics, Raises Price Target to $11
SVB Leerink analyst Mani Foroohar maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Market Perform and raises the price target from $10 to $11.
4D Molecular Therapeutics Q3 EPS $(0.79) Up From $(0.82) YoY
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.79) per share. This is a 3.66 percent increase over losses of $(0.82) per share from the same period last year.